Cristine Radojicic, MD
Allergy & Immunology · Durham, NCNPI 1245294206
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $396,353 of the $557,555 with a category attached, or 71.1%. CSL Behring accounts for 85.6% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $160,863, 3.9 times the $40,770 reported in 2019. Among allergy & immunology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 531 payments — averaging $1050.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$477K
- Ionis Pharmaceuticals, Inc.$22K
- Biocryst Pharmaceuticals, Inc.$21K
- Genentech USA, Inc.$17K
- Pharming Healthcare, Inc.$13K
- Optinose US, Inc.$3K
- plus $4K from 7 others
Across 4 payments — averaging $1012.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$4K
What the payments were for
- Consulting fees$88,84316%
- Speaking & faculty fees$396,35371%
- Travel & lodging$61,37011%
- Food & beverage$10,8662%
- Education$1230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 442 | $477,418 |
| Ionis Pharmaceuticals, Inc. | 15 | $21,963 |
| Biocryst Pharmaceuticals, Inc. | 24 | $21,222 |
| Genentech USA, Inc. | 12 | $16,800 |
| Pharming Healthcare, Inc. | 17 | $12,584 |
| Optinose US, Inc. | 8 | $3,240 |
| Sanofi | 4 | $1,985 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,350 |
| Tersera Therapeutics LLC | 1 | $517 |
| Biocryst US Sales Co., LLC | 4 | $244 |
| GSK | 1 | $90 |
| Shire North American Group Inc | 1 | $88 |
| Alk-abello, Inc | 1 | $55 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$557,555 in reported general payments places this provider in the 95th percentile of 140 allergy & immunology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 21 | $1,072,528 |
| Dupixent PenDupilumab | 64 | $255,793 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $43,392 |
| Breo ElliptaFluticasone/Vilanterol | 70 | $38,433 |
| Epinephrine | 69 | $15,464 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,710 |
| Azelastine Hcl | 139 | $3,560 |
| Wixela InhubFluticasone Propion/Salmeterol | 27 | $3,547 |
| Danazol | 15 | $3,477 |
| Arnuity ElliptaFluticasone Furoate | 11 | $2,890 |
| Mometasone Furoate | 19 | $2,242 |
| Fluticasone Propionate | 117 | $2,038 |
| Ipratropium Bromide | 74 | $1,784 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 38 | $1,213 |
| Montelukast Sodium | 66 | $735 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $1,350 | $1,072,52821 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $90 | $84,714149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 140 allergy & immunology providers in North Carolina.
Other allergy & immunology in Durham
- David PisetskyDurham$31K
- Maeve OconnorCharlotte$2.2M
- Joel HartmanWinston Salem$749K
- Scott ComminsChapel Hill$555K
- William McCannAsheville$486K
- Aerik WilliamsSalisbury$298K
- Karen DunnRaleigh$258K
- Roopen PatelCharlotte$257K
- Jonathan RomeoRaleigh$230K
- John NorrisCharlotte$198K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.